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Abstract
Cerebral malaria (CM) and severe anemia (SA) are the most severe complications of Plasmodium falciparum infections.
Although increased release of endothelial microparticles (MP) correlates with malaria severity, the full extent of vascular cell
vesiculation remains unknown. Here, we characterize the pattern of cell-specific MP in patients with severe malaria. We
tested the hypothesis that systemic vascular activation contributes to CM by examining origins and levels of plasma MP in
relation to clinical syndromes, disease severity and outcome. Patients recruited in Douala, Cameroon, were assigned to
clinical groups following WHO criteria. MP quantitation and phenotyping were carried out using cell-specific markers by
flow cytometry using antibodies recognizing cell-specific surface markers. Platelet, erythrocytic, endothelial and leukocytic
MP levels were elevated in patients with cerebral dysfunctions and returned to normal by discharge. In CM patients, platelet
MP were the most abundant and their levels significantly correlated with coma depth and thrombocytopenia. This study
shows for the first time a widespread enhancement of vesiculation in the vascular compartment appears to be a feature of
CM but not of SA. Our data underpin the role of MP as a biomarker of neurological involvement in severe malaria. Therefore,
intervention to block MP production in severe malaria may provide a new therapeutic pathway.
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Introduction
Malaria still poses a serious threat to human life. According to the
WHO 2008 world malaria report, of 3.3 billion people at risk in 2006,
there were an estimated 247 million malaria cases causing nearly a
million deaths, mostly of children under 5 years. 109 countries were
endemic for malaria in 2008, 45 within the WHO African region
(WHO report http://apps.who.int/malaria/wmr2008/) [1]. Severe
malarial anemia (SA) and cerebral malaria (CM) are the most severe
complications of infections with Plasmodium falciparum (Pf).Insights into
the processes leading to these severe forms might lead to new
interventions that address pathophysiological processes causing
malaria’s peculiar morbidity and mortality [2],[1].
One of the hypotheses to explain the severe malaria excessive
response is the ‘‘all immunological theory’’. It rests on the
accumulation of host cells (including parasitized erythrocytes) in
the brain microvasculature of CM patients. These cells, especially
mononuclear leucocytes and platelets, induce an increased cytokine
and chemokine production. In turn, these inflammatory processes
result in an increased cell activation, which may be reflected, among
other changes, by elevated circulating microparticle levels [3].
Microparticles (MP), also referred to as microvesicles, are
fragments physiologically shed from the plasma membrane of
virtually all cell types. MP are also released during in vitro cell
stimulation and are a marker of cellular activation and apoptosis
or tissue damage occurring in vivo in a variety of pathophysiological
circumstances [4],[5].
Investigations on vesiculation during malaria infection in murine
models have generated valuable data about the physiopathology of
severe malaria [6],[7]. As none of the animal or in vitro models
exactly mimic the human disease; it is essential to investigate these
processes in malaria patients for better understanding [8],[9],[10].
In this line of thought, platelet accumulation has been identified in
the brain microvasculature of patients with CM, suggesting that as
in experimental models, they could be pathogenic in the
neurological syndrome [11]. Recently, a dramatic increase in
plasma levels of MP of endothelial origin has been found in
falciparum-infected Malawian children, specifically in patients with
CM, as opposed to patients with severe malarial anemia (SA) or
uncomplicated malaria (UM) [12]. As cell types other than
endothelial cells, including platelets, monocytes, T lymphocytes
and red blood cells can release MP, it is essential to explore the
diverse cellular origins of MP and to evaluate the extent to which
vesiculation correlates with clinical and biological parameters.
The objective of the present work was thus twofold: firstly, to
characterize and compare MP and their phenotypes in patients
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controls and, secondly, to examine MP phenotypes in relation to
clinical syndromes, disease severity and outcome.
Materials and Methods
Recruitment of patients
The patient recruitment throughout the year 2007 consisted of
the enrolment of children 0 to 15 years old who presented to
participating health institution for health problems in Douala
(Cameroon). Children with diarrhea, non malaria infections and
HIV were excluded. Finally, children who met the study inclusion
criteria were recruited after informed consent and, at a later time
allocated to the different malaria severity groups.
Table 1 provides anthropometric, clinical and hematological
characteristics of the subjects in the 5 groups (UM, SA, CM,
CM+SA and controls). These figures and clinical management have
been presented in more detail elsewhere [13]. Briefly, children with
UM, SA and CM were given quinine base for 3 days. SA patients
also received whole blood prior to quinine and iron supplementa-
tion. CM patients received, after quinine, an artemisinin combina-
tion therapy and iron supplementation. The study protocol was
approved by the Cameroon Bioethics committee and the Provincial
delegation of Public Health. Written consent (informed consent
form) was obtained from most parents/guardians of study
participants. In some cases, only verbal consent was obtained due
to illiteracy in the presence of the physician in charge. Such process
is acceptable by the Cameroon Bioethic committee, as it does not
consider the written consent superior in anyway to the verbally
given consent in circumstances like illiteracy.
Definition of categories
SA was defined as a hemoglobin,8.0 g/dl or a hematocrit,18
in a patient with a positive malaria smear. CM was diagnosed if a
patient with a positive smear presented with impaired conscious-
ness as measured by a Blantyre coma score [14] #2 (range: 0–5)
and had a normal cerebrospinal fluid. Children without any of the
above mentioned symptoms, but presenting with usual malaria
symptoms and a positive smear were classified as UM.
Malaria diagnosis
Positive Pf malaria diagnosis was performed as described
elsewhere [13]. Briefly, diagnosis was made on a thick blood film.
For control subjects, in addition to the thick film, a more sensitive
antigenic test to detect PfHRP2 (P. falciparum-specific Histidin Rich
Protein 2) was performed using ParaHit dipstick (Span Diagnostics
Ltd, India).
Sample collection and processing for MP analysis
Two milliliters of blood were collected by cubital venipuncture in
0.124 M trisodium citrate tube. Within 3 h of collection, platelet
free plasma was prepared as previously described [7] then stored at
280uC. At discharge, another blood collection was performed in
children with severe malaria (CM and SA groups). These aliquots
were shipped on dry ice to the Vascular Immunology Unit, Sydney.
Microparticle analysis
mAbs and reagents. FITC-annexin V, PE-mAbs/isotype-
matched controls (CD3, CD11b/Mac1, CD41/GPIIbIIIa, CD105/
endoglin, CD235a/glycophorin A), as well as FITC-antibodies/
isotype-matched controls (CD51/av subunit of avb3 complex) were
all from Beckman-Coulter-Immunotech, Marseille, France. Annexin
V binding buffer (BB) (106) and FlowcountHfluorospheres were from
Beckman-Coulter, Fullerton, CA.
MP labeling. Total MP (T-MP:annexin V
+) numbers were
determined by detection of phosphatidylserine (PS) using FITC-
annexin V diluted 1:1 in 106BB. In parallel, the cellular origin of
these MP was investigated using cell-specific mAbs. Leukocyte MP
were detected using anti-CD3 (lymphocyte, L-MP:CD3
+) and anti-
CD11b (monocyte, M-MP:CD11b
+); platelet MP with anti-CD41 (P-
Table 1. Anthropometric, clinical and hematological characteristics of subjects in the different groups.
Groups Controls UCM SMA CM CM&SMA
n 3 05 9 4 53 21 0
Male 9 34 27 15 7
Female 21 25 18 17 3
Age (months) 59.0768.82* 41.5665.12 49.9365.71 26.1362.41 36.768.98
Weight (Kg) 19.0561.47 15.6861.22 15.6361.09 12.1860.65 13.2561.27
Temperature (uC) 37.1960.04 38.9160.09 38.6360.10 39.8360.16 39.5760.33
FRT (hours) N/A 34.4062.68 39.1764.08 58.1165.58 9666.41
BCS 560 4.7560.06 4.4260.10 1.6660.10 1.7060.15
CRT (hours) N/A N/A N/A 14.1061.40 2763.71
PRT(hours) N/A 19.0562.80 46.0664.24 52.6764.67 90612.63
Fits frequencies N/A 0.8960.23 1.2860.47 1.6260.56 1.4460.86
Parasites (/ml) N/A 1451862443 67345613512 138007628183 141000650784
WBC (/ml) 73606199 94976330 121526537.6 137866638 1461061174
RBC (X 10
3/ml) 41796104 3986655.58 2292688.40 37536101 26266190
Hgb (g/dl) 12.5260.15 10.9760.16 5.0460.21 10.5660.19 6.4260.42
Platelets (/ml) 204780610199 20778867529 190149611671 12346966796 109000627388
n: number;
*: Mean6SE; FRT: Fever Resolution Time; BCS: Blantyre Coma Score; CRT: Coma Resolution Time; PRT: Prostration Resolution Time; WBC: White blood cells count; RBC:
Red blood cells count; Hgb: Hemoglobin; N/A: Not applicable.
doi:10.1371/journal.pone.0013415.t001
MP: Cerebral Malaria Biomarker?
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+), red blood cell MP with anti-CD235a (R-MP:CD235a
+)
and endothelial MP with PE-anti-CD105 and the FITC-anti-CD51
(E-MP:CD105
+ and E-MP:CD51
+, respectively). The latter was used
in order to further characterize and confirm our previous study on
endothelial MP in Malawi [12].
Briefly, platelet free plasma was diluted in PBS (1:9, V/V),
labeled and resuspended in 200 ml of PBS or BB for annexin V
(16). 20 ml of FlowcountH beads (1000/ml) were added to each well
as an internal standard.
Flow cytometry analysis. Labeled plasma samples were
analyzed on a Beckman-Coulter FC500-MPL flow cytometer. The
MP region was defined using a FSC-SSC dot plot (Fig. 1A) as
described [12]. Data were acquired for 90 sec and positive MP
were discriminated for their binding to specific mAb and annexin
V. Representative cytograms of each type of MP, total and cell-
derived, are shown in Fig. 1B–H. FlowcountH beads were distinct
from the MP population and could thus be counted on the same
cytogram (Fig. 1A). Absolute numbers of MP were then calculated
by the following formula:
MP=ml~
PosEv|TotBeads
CountBeads|Vol
|DilFact
With :
PosEv=Number of positive events in LOG-FL/LOG-SSC;
TotBeads=Total number of beads per well (20000); Count-
Beads=Number of beads counted in 90 sec; Vol=Test volume
(240 ml); DilFact=Dilution factor (120).
Statistical analysis
Data were analyzed using GraphPad-Prism v.5.00, GraphPad
Software, San Diego, CA. A non-parametric analysis of variance
(ANOVA, Kruskall-Wallis with Dunn’s post-test) was used to
compare several groups, while comparison of mean total and cell-
specific MP levels between two different groups (paired samples)
was analyzed with Wilcoxon test. Spearman’s rank correlation
Figure 1. Flow cytometry analysis details and representative cytograms in a CM patient. MP were discriminated by their size and
structures (Fig. 1A). And events in MP gate were further analyzed to differentiate Annexin V
+ MP from the background signal. An internal standard,
constituted of fluorosphere beads of a known size and at a known concentration was used to help set the MP gate and calculate the MP level.
Representative cytograms: 1B to 1H Illustrations of the differences in MP positive events in cytograms representing total MP and cell-derived MP in a
CM patient. (B): T-MP:annexin V
+;( C): P-MP:CD41
+;( D): E-MP:CD105
+;( E): R-MP:CD235a
+;( F): E-MP:CD51
+;( G): M-MP:CD11b
+;( H): L-MP:CD3
+.These
MP positive events were used in the calculations of the number of MP/ml of plasma (see the methods section).
doi:10.1371/journal.pone.0013415.g001
MP: Cerebral Malaria Biomarker?
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MP counts, and clinical as well as biological parameters. P,0.05
(*) was considered significant.
Results
Total and cell-specific MP levels increased on admission
in CM patients
T-MP:annexin V
+ levels were significantly increased in the groups
with cerebral involvement (CM and CM+SA), when compared to
controls, UM, and SA groups (Fig. 2A, 436616, 405613, 408613,
656628, and 580624 MP/ml for control, UM, SA, CM and
CM+SA respectively; P,0.001). The same trend was seen for all cell-
specific MP studied with significant differences between the CM
group and control groups (control, UM and SA) observed: P,0.05
for L-MP:CD3
+ only between C and CM, P,0.001 for E-
MP:CD105
+,P ,0.0001 for P-MP:CD41
+, R-MP:CD235a
+ and
M-MP:CD11b
+ subpopulations; Fig. 2B to F, respectively).
While eachtypeofMP appeared to be represented equally within
the control and UM groups, P-MP:CD41
+ and R-MP:CD235a
+
were the most prevalent in the CM and CM+SA groups, while P-
MP:CD41
+ were the most abundant subpopulation (not shown). In
all groups, the L-MP:CD3
+ were the least represented.
When analyzing for each group the percentage of patients that
display elevated numbers of MP, i.e., above a defined threshold=
mean of control group or mean of control group+2 SD (not shown),
we found that CM and CM+SA were the only groups where at least
65 and 50% of the values, respectively, were higher than the control
group mean, and between ,10 and ,50% were higher than
mean+2 SD. It is worth noticing that in these 2 groups, the P-MP
with levels superior than mean+2SD were found in 43.7 and 30% of
the patients and 50 and 40%have elevated T-MP:annexin V
+ levels.
Endothelial cells release phenotypically and quantitatively distinct
MP. Two distinct specific endothelial antigens were investigated.
While E-MP:CD51
+ numbers were lower than E-MP:CD105
+ ones,
a significant positive correlation was obtained between the two
determinations (r
2=0.4786, P,0.0001, not shown).
Total and cell-specific MP levels at follow-up/discharge
To evaluate the relationship between MP levels and clinical
improvement, another blood sample was collected from children
with SA and/or CM, at discharge.
In the CM groups, the high levels of T-MP:annexin V
+ seen on
admission dramatically decreased from 656628 MP/mlo na d m i s s i o n
to 455640 MP/ml( p ,0.0009) at discharge to return within the
normal range (Fig. 3A). When, only paired samples were analyzed, 13
out 15 (87%) were significantly lower on discharge (p=0.0002). P-
MP:CD41
+,E - M P : C D 1 0 5
+ and R-MP:CD235a
+ levels also all
decreased significantly at discharge (Fig. 3B: p=0.0004, C:
p=0.0099 and D: p=0.0028, respectively). Again, when only paired
samples were observed 13 to 14 out of 15 samples (87 to 93%) were
significantly decreased (P-MP:CD41
+: p=0.0067, E-MP:CD105
+:
p=0.007 and R-MP:CD235a
+: p=0.0005, respectively). Even
though 53 and 60% of L-MP:CD3
+ and M-MP:CD11b
+ levels,
respectively, were decreased at discharge, no statistical difference was
observed (Fig. 3E and F).
Figure 2. Total and cell-specific MP levels per ml of plasma on admission in the different groups. (A): T-MP:annexin V
+;( B): P-MP:CD41
+;
(C): E-MP:CD105
+;( D): R-MP:CD235a
+;( E): M-MP:CD11b
+;( F): L-MP:CD3
+. Dot plots representations showing elevations of total MP and the different
cell-specific MP investigated in CM and CM+SA patients. C: Controls; UM: uncomplicated malaria; SA: severe malaria anemia patients on admission;
CM: cerebral malaria patients on admission; CM+SA: patients with the combine symptoms of CM and SA on admission; MP levels are given in MP/mlo f
plasma. *: p,0.05, **: p,0.001, ***: p,0.0001.
doi:10.1371/journal.pone.0013415.g002
MP: Cerebral Malaria Biomarker?
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MP:CD235a
+ levels between paired samples at admission and
discharge (2564M P / mlt o7 3 612 MP/ml, p,0.0035, Fig. 3D) where
11 out of the 14 samples (78%) displayed this increase. Although no
statistical difference was observed total, L-MP:CD3
+, M-MP:CD11b
+
and E-MP:CD105
+ levels also tended to increase at discharge.
Due to a low number of discharge samples, no significant
difference was observed between the CM+SA groups, however it is
also worth noticing that all MP levels decreased at discharge
(Fig. 3A to F).
Correlations between MP levels and clinical or biological
parameters
We investigated possible correlations between MP and some
clinical and biological parameters obtained during patient recruit-
ment, namely age, temperature on admission, fever resolution time
(FRT), Blantyre coma score (BCS), coma resolution time (CRT),
prostration resolution time (PRT), parasitaemia, hemoglobin level
and white blood cell, red blood cell, and platelet counts. In the CM
group, we found negative correlations between P-MP:CD41
+ and
temperature (r=20.343, P=0.0545), FRT (r=20.571, P=0.0106),
BCS (r=20.437, P=0.0122), CRT (r=20.524, P=0.0176), and
platelet count (r=20.397, P=0.0244) (Fig. 4 A–E). In the SA group,
hemoglobin level and R-MP:CD235a
+ were positively correlated
(r=0.359, p=0.0154) (Fig. 4F); however, there was no correlation
between red blood cell counts and R-MP:CD235a
+ levels in the SA
group (r=0.100, P=0.5118) nor between parasitaemia and MP
levels.
Due to the different numbers of males and females in some
groups, we investigated total and cell-specific MP levels in males
versus females. No statistical difference was obtained in any of the
MP subpopulations.
MP in CM fatal cases and in CM survivors
During the course of patient recruitment, death occurred in 5
patients, all in the CM group. We compared total and cell-specific
MP levels in survivors and fatal cases. No statistical difference was
obtained except for E-MP:CD105+, where we found 78.8568.37
EMP/ml in those who survived compared to 130.6633.14 E-
MP:CD105
+/ml in those who died (p=0.0370). The values from
the deceased patients are presented as black stars on Figure 3.
Discussion
We report here, in patients with severe malaria, elevated MP
numbers and, for the first time, a detailed analysis of their cellular
origin. During the last ten years, a growing number of studies have
Figure 3. Total and cellular MP levels per ml of plasma at follow-up/discharge (7 days after admission: A) versus levels on admission. (A):
T-MP:annexin V
+;( B): P-MP:CD41
+;( C): E-MP:CD105
+;( D): R-MP:CD235a
+;( E): M-MP:CD11b
+;( F): L-MP:CD3
+. Dot plot representations showing how in
most of the cases, MP levels decreases in patients with CM at discharge (D). Control group is represented to show that patient levels are returning to
control levels. C: Controls; SA: severe malaria anemia patients on admission; CM: cerebral malaria patients on admission; CM+SA: patients with the
combine symptoms of CM and SMA on admission; SA(D): severe malaria anemia patients at discharge; CM(D): cerebral malaria patients at discharge;
CM+SA(D): patients with the combine symptoms of CM and SMA at discharge; MP levels are given in MP/ml of plasma. The values of the deceased
patients are presented as black stars on Figure 3. *: p,0.05, **: p,0.001, ***: p,0.0001.
doi:10.1371/journal.pone.0013415.g003
MP: Cerebral Malaria Biomarker?
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fever resolution time (FRT), Blantyre coma score (BCS), coma resolution time (CRT) and platelet counts, respectively. F: correlation between R-MP and
hemoglobin levels (Hgb).
doi:10.1371/journal.pone.0013415.g004
MP: Cerebral Malaria Biomarker?
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with various disease states, as well as studies investigating the
composition and functional characteristics of MP [15],[12],[16].
Moreover, a role for MP in the pathogenesis of the disease is
supported by the fact that, in experimental CM, (i) MP levels are
increased in the plasma of mice at the time of the development of
the neurological syndrome [7], (ii) the absence of MP overpro-
duction is associated with protection against experimental CM
without altering the parasitaemia [7],[17]. Knock-out mice
deficient for the abca1 gene that do not up-regulate MP production
in response to vesiculation agonists, are fully protected against
experimental CM and display normal levels of plasma MP when
their wild type CM-susceptible littermates show the onset of the
syndrome [7]. In addition, when treated with pantethine, a
physiological substance and co-enzyme A precursor in the Krebs
cycle, used in patients for its hypolipemic properties [18],[19],[20],
infected mice are protected against experimental CM and do not
show elevated levels of plasma MP as their non treated littermates
do [17]. We had previously reported dramatically increased
endothelial MP levels in the peripheral blood of Malawian
children with malaria, and this increase was restricted to patients
with CM [12]. Here we sought to better understand this finding by
investigating, in another malaria endemic country, endothelial
MP, but also total MP along with MP from lymphocytes,
monocytes, platelets and erythrocytes.
In this study we have analysed separately the different types of
MP. Single stainings have been performed for each marker
(annexin V or monoclonal antibody). Several studies have
described the presence of MP that do not bind annexin V
[3,21]. It is not known whether this is due to a lack of
phosphatidylserine at the surface of MP or levels of phosphatidyl-
serine that are undetectable by current flow cytometers. Since
the significance of these annexin V «negative» MP remains to be
elucidated, we have chosen to perform single stainings. Also, the
antigens we have chosen to detect at the surface of MP are specific
for cell types and there is no co-expression between the different
types of MP analysed here. Although we have not performed
double staining, since the number of annexin V positive MP for a
patient is generally equal or superior to the sum of all MP detected
with specific antibodies, it is likely that most of these MP are
annexin V positive.
Total and cell-specific MP levels were found to be elevated in
CM patients whereas only total MP levels were higher than
controls in both groups with cerebral involvement (CM and
CM+SA). Those increased levels suggest the activation of a broad
range of immune cells during CM as well as their alteration,
secondary to the cerebral processes [22,23]. We found that M-
MP:CD11b
+, P-MP:CD41
+, E-MP:CD105
+ and R-MP:CD235a
+
were increased in CM- associated vesiculation processes and, to a
lower extent, L-MP:CD3
+. In the murine model of CM, brain
vessels at the time of the neurological syndrome showed focal
accumulation of monocytes [24] and platelets. The latter are seen
in both human and murine CM [25],[11]. Pf-infected erythrocyte
sequestration in the microvasculature is the major feature of CM
histopathology leading to the disruption of the blood-brain barrier.
This sequestration is observed in almost all organs, including the
brain [26] and could explain increased MP levels which could be
specific to malaria with cerebral involvement. In this particular
study, determination of the parasite load via assaying the parasite-
derived lactate dehydrogenase (pLDH) in the post-mortem tissues
[27] was not performed as the ethical consent in Cameroon was
only for blood samples and the number of deceased patients was
low (n=5). In the Malawian study [27], the results of the p-LDH
assay had suggested that levels of sequestration are higher in most
organs for patients who died of CM than patients with assumed
CM then diagnosed as non CM at autopsy.
MP carry at their surface proteins able to allow their binding to
target cells, but also mediate cell–cell interactions through cell
adhesion molecules or simple contact. Moreover, MP are able to
transfer antigens from their originating cell to another
[3],[28],[29]. Thus, the cells involved in the vesiculation increase
are also those involved in sequestration [5].
In SA patients, we observed a decrease in R-MP:CD235a
+.S A
is due to the destruction of both parasitized and non-infected
erythrocytes [30]. A greater number of R-MP:CD235a
+ in SA
patients could be expected, as for the thrombocytopenia seen in
CM, but was not observed. This could be explained by a long
time-course pathology with chronic and/or repeated infections
that has lead to a gradual decrease of RBC and hemoglobin
concentration [31],[32]. This may also result in the clearance of
MP, and SA patients might have consulted after their R-MP had
already been cleared by the immune system [33].
Total and cell-specific MP were also investigated when children
were discharged. In children with CM, MP were decreasing and,
for most of them, returned to control values. Due to small patient
numbers, statistical tests did not reach significance for the CM+SA
group even though a marked decrease was observed between
admission and follow-up values in the whole population and in
paired samples. This is consistent with previous findings where E-
MP:CD51
+ levels returned to normal at convalescence [12]. Apart
from immune MP clearance, these MP level reductions in
discharged CM patients could be associated with the disappear-
ance of neurological manifestations such as coma, fits or palsies
[2].
By contrast, in the SA group, we observed a trend to increased
MP levels at discharge. SA patients with low RBC count and
hemoglobin concentration on admission received whole blood
transfusions before and between their anti-malarial therapies.
Blood packs were obtained from donors at the blood bank of
hospitals. Aside from cold storage, blood packs were not submitted
to any processing. MP shedding is known to increase spontane-
ously at 4uC and stored platelets shed more MP than fresh platelets
do [34]. We can thus hypothesize that the observed increase of
cell-specific MP levels in SA patients could be due to the MP
generated during the storage of blood prior to transfusion, and/or
some anaphylactic reactions due to blood incompatibilities in the
recipient incidental to the transfusion [35].
Circulating MP levels were found to correlate with a number of
clinical and biological parameters. In CM patients, the P-
MP:CD41
+ increase was associated with the depth and duration
of the coma, as indicated by the negative correlations between P-
MP:CD41
+ levels and BCS and CRT. In our clinical setting, one
could not predict the coma duration based solely on how deep the
coma was. Indeed, the cause of impaired consciousness was
generally unclear and coma likely to result from several interacting
mechanisms [2]. In addition, a negative correlation between P-
MP:CD41
+ and platelet counts was found. This suggests that CM-
associated thrombocytopenia is characterized by P-MP release.
This is consistent with previous studies in the murine model and
supports the view that platelets are involved in the neurovascular
injury during CM [25],[11]. It is tempting to hypothesize that,
despite a marked thrombocytopenia, attributed to both platelet
destruction and platelet sequestration in various organs [11],[36],
these P-MP:CD41
+, because they are still present in the
circulation, could be responsible for some of the platelet-related
effects such as activation of coagulation or adhesion. All these
processes would contribute to the neurovascular lesions and
emphasize the pivotal role of platelets in CM pathogenesis [3].
MP: Cerebral Malaria Biomarker?
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infected erythrocytes, there was no correlation between parasitae-
mia and R-MP:CD235a
+ levels. It is noteworthy that in malaria
endemic contexts, most patients coming to hospital have already
taken some treatments (self medication prior to admission), a
factor which may influence the parasitaemia assessment [37]. Also,
no link was observed between MP levels and gender supporting
the idea that vesiculation changes occur indiscriminately in both
genders, as CM symptoms and signs do. In conclusion, we report
here the presence of higher levels of total and cell-specific MP in
CM patients but not in those with SA or UM and clearly
demonstrate their value as a biomarker in the CM pathogenesis.
To our knowledge, it is the first time that the diverse cellular
origins of MP and their association with some cerebral
dysfunctions and biological parameters have been investigated in
pediatric severe malaria. This study validates that sequestration
occurring in deep microvessels during CM involves a broad range
of vascular cells, particularly platelets, erythrocytes, monocytes
and endothelial cells. MP, and most notably those from platelet
origin appear to be a relevant marker in the follow up of patients
with CM because (i) their levels were the highest, (ii) they
correlated with important clinical and biological parameters such
as coma score and platelets counts and (iii) they returned to normal
values when the patient was cured, making this parameter a
potentially useful indicator of the efficiency of patient manage-
ment. MP enumeration is a simple and rapid assay that could be
implemented in hospitals dealing with malaria patients and
equipped with a flow cytometer to allow analysis on fresh plasma
or even whole blood. Further kinetics studies are required to define
whether elevated MP numbers can be considered as a predictive
marker of severity for malaria patients.
Altogether, the previous results on the pathogenesis of MP in
experimental CM and the patient data generated in this study
warrant the use of MP as biomarker during severe malaria
infection and support further pharmacological studies aiming at
decreasing their production.
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